Sobi and Innate announce partnership is now effective following completion of closing conditions
Sobi and Innate Pharma's strategic partnership is now effective after the applicable antitrust waiting periods expired and closing conditions were completed, triggering a $75 million upfront payment from Sobi to Innate. The deal enables the TELLOMAK-3 confirmatory Phase 3 study of lacutamab in cutaneous T-cell lymphoma, with the first patient expected in Q1 2027, supporting a planned accelerated approval filing in Sézary syndrome.
Key figures
- Drug Name
- lacutamab
- Phase Of Trial
- Phase 3
- Indication
- cutaneous T-cell lymphoma / Sézary syndrome
- Trial name
- TELLOMAK-3
- Royalty terms
- tiered double-digit royalties on net sales
- Upfront payment usd
- 75000000
- First patient expected
- Q1 2027
- Near term milestone potential usd
- 40000000
- Option and milestone potential usd
- 465000000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.